Please use this identifier to cite or link to this item:
Title: Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges
Author: Cano Fernández, Amanda
Turowski, Patrick
Ettcheto Arriola, Miren
Duskey, Jason Thomas
Tosi, Giovanni
Sánchez-López, E. (Elena)
García López, María Luisa
Camins Espuny, Antoni
Souto, Eliana B.
Ruiz, Agustín
Marquié, Marta
Boada, Mercè
Keywords: Malalties neurodegeneratives
Malaltia d'Alzheimer
Neurodegenerative Diseases
Alzheimer's disease
Issue Date: 1-Dec-2021
Publisher: BioMed Central
Abstract: t Increasing life expectancy has led to an aging population, which has consequently increased the prevalence of dementia. Alzheimer's disease (AD), the most common form of dementia worldwide, is estimated to make up 50-80% of all cases. AD cases are expected to reach 131 million by 2050, and this increasing prevalence will critically burden economies and health systems in the next decades. There is currently no treatment that can stop or reverse disease progression. In addition, the late diagnosis of AD constitutes a major obstacle to efective disease management. Therefore, improved diagnostic tools and new treatments for AD are urgently needed. In this review, we investigate and describe both well-established and recently discovered AD biomarkers that could potentially be used to detect AD at early stages and allow the monitoring of disease progression. Proteins such as NfL, MMPs, p-tau217, YKL-40, SNAP-25, VCAM-1, and Ng / BACE are some of the most promising biomarkers because of their successful use as diagnostic tools. In addition, we explore the most recent molecular strategies for an AD therapeutic approach and nanomedicine-based technologies, used to both target drugs to the brain and serve as devices for tracking disease progression diagnostic biomarkers. State-of-the-art nanoparticles, such as polymeric, lipid, and metal-based, are being widely investigated for their potential to improve the efectiveness of both conventional drugs and novel compounds for treating AD. The most recent studies on these nanodevices are deeply explained and discussed in this review. Keywords: Alzheimer's disease, Biomarkers, Polymeric nanoparticles, Lipid nanoparticles, Metal nanoparticles, Nanotechnology
Note: Reproducció del document publicat a:
It is part of: Journal of Nanobiotechnology, 2021, vol. 19, num. 1, p. 1-30
Related resource:
ISSN: 1477-3155
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
714432.pdf1.86 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons